arrow
E

Emmanouil Spanoudakis

democritus university of thrace
H指数:16
被引数:1,074

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high-risk myelodysplastic syndromes

腺苷能通路在高风险骨髓增生异常综合征患者对去甲基化药物耐药中的作用

2026-09-060
OAAI
Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model

西妥昔单抗单药治疗与利妥昔单抗为基础的治疗相比,可改善特发性多中心性Castleman病患者的无进展生存期;采用单臂Meta分析方法和广义线性混合模型对研究进行间接比较。

2025-12-050
OAAI
Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration

拉瓦鲁zumab(Ravulizumab)能够稳定由抗-e和抗-Jka同种抗体引起的延迟性溶血性输血反应后的危及生命血管内溶血:首次成功给药。

2025-08-280
OAAI
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia

继发性原发性恶性肿瘤及症状性华氏巨球蛋白血症患者的疾病转化

2025-06-120
OAAI
Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

真实世界研究中接受teclistamab和talquetamab治疗的复发/难治性多发性骨髓瘤患者的结局;希腊骨髓瘤研究小组的多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group

早期女性生殖道弥漫性大b细胞淋巴瘤的临床特征和预后: 希腊合作淋巴瘤组的回顾性研究

2024-08-062
PRE
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group
2024-07-020
PRE
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group
2023-03-1610
PRE
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World POWERFUL Study
2021-04-052
OAAI
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas
2021-03-0228
PREAI
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival (vol 97, pg 1671, 2018)
2018-06-260
OAAI
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
2018-05-1318
OAAI